Gregory T. Bates, DVMSenior Vice President, Regulatory Affairs

    Gregory T. Bates, DVM joins Axial with thirty years of international pharmaceutical industry experience, including twenty-seven years in regulatory affairs covering the regulation of drugs and biologics. Prior to joining Axial, Dr. Bates served as Vice President of Regulatory Affairs at Depomed, Inc. (NASDAQ: DEPO), where he provided regulatory strategies for the product teams managing the Company’s development-stage and commercialized pain therapeutics and managed the Company’s regulatory affairs and regulatory operations staff. For 10 years, Dr. Bates was part of the senior management team at XenoPort, Inc. (NASDAQ: XNPT), including four years as Senior Vice President of Regulatory Affairs and Quality and successfully led the Company’s NDA and sNDA filings and approvals for its restless legs syndrome treatment drug, Horizant® (gabapentin enacarbil). Prior to XenoPort, Dr. Bates served as Director and Senior Director of Regulatory Affairs at Pharmacyclics, Inc., directing its regulatory operations group and coordinating communications with global regulatory agencies. His career is further highlighted by Regulatory Affairs positions at Genentech, Inc. and Syntex (U.S.A.), Inc. Dr. Bates received his Doctor of Veterinary Medicine (DVM) degree from the University of California, Davis and holds a bachelor’s degree in Human Physiology from the University of California, Berkeley.